Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study

Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?"

(2022) Matteo Megna et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study

(2022) Matteo Megna et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

(2022) Jeffrey J. Crowley et al.   Dermatology and Therapy

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

(2021) Matteo Megna et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

(2021) Angelo Ruggiero et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?

(2021) Matteo Megna et al.   Dermatologic Therapy

Reply to “Psoriasis exacerbation after Covid‐19 vaccination: report of 14 cases from a single center” by Sotiriou E et al.

(2021) M. Megna et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

(2021) A. Ruggiero et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA ( EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study

(2021) Delia Colombo et al.   Dermatologic Therapy

Anti‐IL17 and anti‐IL23 biologic drugs for scalp psoriasis: A single‐center retrospective comparative study

(2021) Alessandra Narcisi et al.   Dermatologic Therapy

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

(2021) Angelo Ruggiero et al.   Dermatologic Therapy

Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

(2021) Raquel Rivera-Díaz et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series

(2021) Noha Mohammed Dawoud et al.   Indian Journal of Dermatology Venereology & Leprology

Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”

(2021) Luca Potestio et al.   Journal of Cosmetic Dermatology

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials

(2021) Mark G. Lebwohl et al.   Dermatology and Therapy

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

(2021) Matteo Megna et al.   Biomedicines

Comparison of Biologics and Oral Treatments for Plaque Psoriasis

(2020) April W. Armstrong et al.   JAMA Dermatology

Switching biologics in psoriasis - practical guidance and evidence to support

(2020) Ya-Chu Tsai et al.   Expert Review of Clinical Pharmacology

Novel Therapeutic Approaches And Targets For Treatment Of Psoriasis

(2020) G. Radi et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: preliminary data of a real‐life 16‐week retrospective study

(2020) Matteo Megna et al.   Dermatologic Therapy

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic

(2020) K. Hansel et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis

(2020) Matthias Augustin et al.   JAMA Dermatology

A case of erythrodermic psoriasis successfully treated with ixekizumab

(2019) Matteo Megna et al.   Dermatologic Therapy

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

(2019) M. Napolitano et al.   BRITISH JOURNAL OF DERMATOLOGY

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis

(2019) Paolo Gisondi et al.   CURRENT OPINION IN PHARMACOLOGY

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

(2019) Kristian Reich et al.   LANCET

Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

(2018) Matteo Megna et al.   CLINICAL RHEUMATOLOGY

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints

(2018) Marie-Astrid Boutet et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs

(2018) M. Megna et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders

(2018) M.J. Gooderham et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

Psoriasis and comorbid diseases

(2017) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis

(2017) G. Girolomoni et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY